Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.

PloS one·2026
Same author

The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.

Frontiers in bioengineering and biotechnology·2026
Same author

Serological Benefit of SARS-CoV-2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia.

Pediatric blood & cancer·2026
Same author

SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.

Antibodies (Basel, Switzerland)·2026
Same author

Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.

Clinical & translational immunology·2026
Same author

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Clinical therapeutics·2026

Related Experiment Video

Updated: Jun 19, 2026

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Towards proteome scale antibody selections using phage display.

Michael Mersmann1, Doris Meier, Jana Mersmann

  • 1Technische Universität Braunschweig, Institute of Biochemistry and Biotechnology, Braunschweig, Germany.

New Biotechnology
|November 4, 2009
PubMed
Summary

This study generated over 90 highly specific single-chain variable fragment (scFv) antibodies using phage display and streamlined methods. The in vitro antibody generation pipeline proved efficient for producing renewable antibody resources at proteome scale.

More Related Videos

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits
12:36

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits

Published on: February 16, 2014

Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing
12:04

Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing

Published on: October 3, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits
12:36

A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits

Published on: February 16, 2014

Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing
12:04

Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing

Published on: October 3, 2018

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Biology

Background:

  • In vitro antibody generation is crucial for research and diagnostics.
  • Phage display offers a powerful platform for antibody discovery.
  • High-throughput methods are needed to meet the demand for diverse antibody specificities.

Purpose of the Study:

  • To generate a large panel of monoclonal antibodies against diverse antigens, including 20 SH2 domains.
  • To evaluate the efficiency and robustness of streamlined, high-throughput antibody generation methods.
  • To validate the generated antibodies for specificity and utility in various applications.

Main Methods:

  • Utilized phage display technology with a large universal gene library for antibody panning.
  • Employed streamlined, high-throughput methods from the 'Antibody Factory' (NGFN).
  • Analyzed 2668 clones, identifying 347 primary ELISA hits, with 90+ scFv antibodies generated against SH2 domains and other antigens.

Main Results:

  • Successfully generated over 90 unique scFv antibodies against 20 SH2 domains and other antigens.
  • Demonstrated high efficiency with a significant number of validated antibody binders from initial screening.
  • Validated antibody specificity using cross-reactivity ELISA, western blot, and protein microarrays.

Conclusions:

  • The in vitro antibody selection pipeline is versatile and efficient for generating a renewable resource of specific monoclonal antibodies.
  • Streamlined high-throughput methods significantly reduce effort and time for antibody production.
  • This approach enables proteome-scale antibody generation with high specificity and reliability.